Celyad

OverviewSuggest Edit

Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.

TypePublic
Founded2007
HQMont-Saint-Guibert, BEMap
Websitecelyad.com
View Jobs (1)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)80
Job Openings1
Revenue (FY, 2017)€3.5 M(-58%)
Share Price (Mar 2017)€20.2 (-3%)

Key People/Management at Celyad

Christian Homsy

Christian Homsy

Executive Director, CEO
Patrick Jeanmart

Patrick Jeanmart

CFO, Investor Relations
Jean-Pierre Latere

Jean-Pierre Latere

Chief Operating Officer (COO)
Frederic Lehmann

Frederic Lehmann

VP Clinical Development and Medical Affairs
David Gilham

David Gilham

VP Research & Development
Philippe Dechamps

Philippe Dechamps

Chief Legal Officer
Show more

Celyad Office Locations

Celyad has offices in Mont-Saint-Guibert and Boston
Mont-Saint-Guibert, BE (HQ)
2 Rue Edouard Belin
Boston, US
2 Seaport Ln
Show all (2)

Celyad Financials and Metrics

Celyad Revenue

Embed Graph
View revenue for all periods
Celyad's revenue was reported to be €3.54 m in FY, 2017 which is a 58.5% decrease from the previous period.
EUR

Revenue (FY, 2017)

3.5m

Revenue growth (FY, 2016 - FY, 2017), %

(58.5%)

Gross profit (FY, 2017)

3.0m

Gross profit margin (FY, 2017), %

85.5%

Net income (FY, 2017)

(56.4m)

EBIT (FY, 2017)

(52.9m)

Market capitalization (22-Mar-2017)

190.4b

Closing stock price (22-Mar-2017)

20.2

Cash (31-Dec-2017)

23.3m

EV

190.4b
Celyad's current market capitalization is €190.4 b.
EURFY, 2015FY, 2016FY, 2017

Revenue

3.0k8.5m3.5m

Revenue growth, %

284000%(58%)

Cost of goods sold

1.0k53.0k515.0k

Gross profit

2.0k8.5m3.0m
show all
EURFY, 2015FY, 2016FY, 2017

Cash

100.2m48.4m23.3m

Accounts Receivable

549.0k1.4m233.0k

Current Assets

109.4m85.4m36.4m

PP&E

1.1m3.6m3.3m
show all
EURFY, 2015FY, 2016FY, 2017

Net Income

(29.1m)(23.6m)(56.4m)

Depreciation and Amortization

273.0k760.0k966.0k

Accounts Payable

1.1m(740.0k)(2.5m)

Cash From Operating Activities

(27.3m)(24.7m)(44.4m)
show all
EURY, 2017

EV/EBIT

-3.6 k x

EV/CFO

-4.3 k x

Revenue/Employee

44.0k

Financial Leverage

1.6 x
Show all financial metrics

Celyad Online and Social Media Presence

Celyad's Trends

Embed Graph

Celyad News and Updates

October 02, 2019

Celyad Announces October and November 2019 Investor Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to participate at the following investor…
October 02, 2019

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that clinical data on the company’s pipeline of candidates will be p…
September 12, 2019

Celyad Announces Pricing of $20.0 Million Global Offering

MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the pricing of a global offering of 2,000,000 ordinary shares, comp…
September 11, 2019

Celyad Announces Launch of Proposed Global Offering

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it intends to offer and sell, subject to market and other conditions, up to 2,000,000 ordinary sha…
September 04, 2019

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of CYAD-01 produced with the Op…
August 22, 2019

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

MONT-SAINT-GUIBERT, Belgium, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced its consolidated financial results for the first half of 2019 and pr…
Show more

 Celyad Frequently Asked Questions

  • When was Celyad founded?

    Celyad was founded in 2007.

  • Who are Celyad key executives?

    Celyad's key executives are Christian Homsy, Patrick Jeanmart and Jean-Pierre Latere.

  • How many employees does Celyad have?

    Celyad has 80 employees.

  • What is Celyad revenue?

    Latest Celyad annual revenue is €3.5 m.

  • What is Celyad revenue per employee?

    Latest Celyad revenue per employee is €44.3 k.

  • Who are Celyad competitors?

    Competitors of Celyad include Alnylam Pharmaceuticals, Sorrento Therapeutics and Moderna Therapeutics.

  • Where is Celyad headquarters?

    Celyad headquarters is located at 2 Rue Edouard Belin, Mont-Saint-Guibert.

  • Where are Celyad offices?

    Celyad has offices in Mont-Saint-Guibert and Boston.

  • How many offices does Celyad have?

    Celyad has 2 offices.